| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8213371 | International Journal of Radiation Oncology*Biology*Physics | 2017 | 31 Pages |
Abstract
From the findings of the largest report of SABR for stage T1-T2N0 SCLC to date, SABR (â¥50 Gy) with chemotherapy should be considered a standard option.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Vivek MD, Charles B. MD, Pamela K. PhD, Sameer R. BS, Chirag MD, Weining MD, Matthew M. MD, Christopher L. MD, Salma K. MD, Chance L. MD, Steve E. MD, PhD, Percy MD, Thomas J. MD, Bryan G. MD, PhD, Elizabeth M. MD, Albert MD, Jing MD, Tithi MD,